1-8 of 8
Andrew D. Seidman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases

Aki Morikawa, Elisa de Stanchina, Elena Pentsova, Margaret M. Kemeny, Bob T. Li, Kendrick Tang, Sujata Patil, Martin Fleisher, Catherine Van Poznak, Larry Norton, Andrew D. Seidman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3784–3792.
https://doi.org/10.1158/1078-0432.CCR-18-3502
Published: 01 July 2019
View article titled, Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases
Open the PDF for Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Maura N. Dickler, Hope S. Rugo, Carey A. Eberle, Edi Brogi, James F. Caravelli, Katherine S. Panageas, Jeff Boyd, Benjamin Yeh, Diana E. Lake, Chau T. Dang, Teresa A. Gilewski, Jacqueline F. Bromberg, Andrew D. Seidman, Gabriella M. D'Andrea, Mark M. Moasser, Michele Melisko, John W. Park, Janet Dancey, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7878–7883.
https://doi.org/10.1158/1078-0432.CCR-08-0141
Published: 01 December 2008
View article titled, A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Open the PDF for A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer

Monica N. Fornier, Andrew D. Seidman, Diana Lake, Gabriella D'Andrea, Jacqueline Bromberg, Mark Robson, Catherine Van Poznak, Katherine S. Panageas, Marietta Atienza, Larry Norton, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (1): 223–227.
https://doi.org/10.1158/1078-0432.CCR-06-1731
Published: 02 January 2007
View article titled, Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Open the PDF for Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer in another window
Journal Articles

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

Chau T. Dang, Gabriella M. D’Andrea, Mary E. Moynahan, Maura N. Dickler, Andrew D. Seidman, Monica Fornier, Mark E. Robson, Maria Theodoulou, Diana Lake, Violante E. Currie, Arti Hurria, Katherine S. Panageas, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (17): 5754–5761.
https://doi.org/10.1158/1078-0432.CCR-04-0634
Published: 08 September 2004
View article titled, Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Open the PDF for Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer in another window
Journal Articles

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Chau T. Dang, Andrew J. Dannenberg, Kotha Subbaramaiah, Maura N. Dickler, Mark M. Moasser, Andrew D. Seidman, Gabriella M. D’Andrea, Maria Theodoulou, Katherine S. Panageas, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4062–4067.
https://doi.org/10.1158/1078-0432.CCR-03-0463
Published: 24 June 2004
View article titled, Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
Open the PDF for Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments in another window
Journal Articles

Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel

Deborah Toppmeyer, Andrew D. Seidman, Michael Pollak, Christy Russell, Katherine Tkaczuk, Shailendra Verma, Beth Overmoyer, Varun Garg, Ene Ette, Matthew W. Harding, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 670–678.
Published: 01 March 2002
View article titled, Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Open the PDF for Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel in another window
Journal Articles

Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma

Monica N. Fornier, Andrew D. Seidman, Maria Theodoulou, Mary Ellen Moynahan, Violante Currie, Mark Moasser, Nancy Sklarin, Theresa Gilewski, Gabriella D’Andrea, Rori Salvaggio, Kathy S. Panageas, Larry Norton, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 3934–3941.
Published: 01 December 2001
View article titled, Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide <em>versus</em> Concurrent Paclitaxel and Cyclophosphamide: <subtitle>5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma</subtitle>
Open the PDF for Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide <em>versus</em> Concurrent Paclitaxel and Cyclophosphamide: <subtitle>5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma</subtitle> in another window
Journal Articles

Phase I Study of Escalating Doses of Edatrexate in Combination with Paclitaxel in Patients with Metastatic Breast Cancer

Gabriella D’Andrea, David Fennelly, Larry Norton, Jose Baselga, Teresa Gilewski, Clifford Hudis, Mary Ellen Moynahan, George Raptis, Nancy Sklarin, Antonella Surbone, Maria Theodoulou, Mary Agnes Templeton, Tzy-Jyun Yao, Andrew D. Seidman
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (2): 275–279.
Published: 01 February 1999
View article titled, Phase I Study of Escalating Doses of Edatrexate in Combination with Paclitaxel in Patients with Metastatic Breast Cancer
Open the PDF for Phase I Study of Escalating Doses of Edatrexate in Combination with Paclitaxel in Patients with Metastatic Breast Cancer in another window